---
layout: default
title: Nimodipine
parent: 僅模型預測 (L5)
nav_order: 706
evidence_level: L5
indication_count: 10
---

# Nimodipine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nimodipine: From Cerebral Vasospasm (Subarachnoid Hemorrhage) to Homozygous Familial Hypercholesterolemia

## One-Sentence Summary

Nimodipine is a lipophilic, cerebrovascular-selective dihydropyridine calcium channel blocker traditionally used to prevent and treat cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The TxGNN model predicts it may be effective for **Homozygous Familial Hypercholesterolemia**, but this specific pairing currently has **0 clinical trials** and **0 publications** supporting it, and the underlying rationale flags no known biological connection between the two conditions.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (drawn from repurposing-rationale context; not independently confirmed by market registration data, which is empty) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for nimodipine is flagged as a data gap in this evidence pack. Based on drug-class information available elsewhere in the pack, nimodipine is an L-type calcium channel blocker with pronounced cerebrovascular selectivity, historically used to reduce delayed cerebral ischemia after subarachnoid hemorrhage.

Homozygous familial hypercholesterolemia is caused by LDL-receptor gene defects leading to severely impaired clearance of LDL cholesterol — a lipid-metabolism disorder with no established link to calcium-channel physiology. The evidence pack's own mechanistic assessment for this pairing is explicit: there is **no known biological connection** between calcium-channel blockade and LDL-receptor-mediated lipid metabolism.

Given the very high TxGNN score (99.29%) combined with a complete absence of clinical trial or literature support, this prediction most likely reflects the model fitting a knowledge-graph co-morbidity or co-prescription pattern rather than capturing a genuine pharmacological signal. It should be treated as a hypothesis-generation output only, not as evidence of therapeutic plausibility.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Singapore Market Information

Nimodipine is not currently registered or marketed in Singapore (0 authorizations on file), so no product-level licensing table is available.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The prediction carries a high TxGNN confidence score but is backed by zero clinical trials and zero literature references, and the pack's own mechanistic review found no plausible biological link between nimodipine's calcium-channel activity and LDL-receptor-driven hypercholesterolemia — the profile of an L5 (model-prediction-only) candidate.
- For context, other candidates generated in this same batch (e.g., congestive heart failure, rank 3) have a larger — though still low-relevance — evidence base (3 trials, 19 publications), which may warrant separate evaluation ahead of this one.

**To proceed, the following is needed:**
- Resolution of DG001 (TFDA/label warnings and contraindications — flagged Blocking, required before any S1 safety screening) and DG002 (confirmed mechanism of action from DrugBank — flagged High severity)
- Independent mechanistic or preclinical rationale connecting calcium-channel blockade to lipid metabolism/LDL clearance, if any exists, before further investment
- Ongoing literature/trial monitoring, since no supporting evidence currently exists for this specific drug–disease pair
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

